AnaptysBio Inc (NASDAQ:ANAB) reached a new 52-week high on Thursday . The company traded as high as $84.75 and last traded at $79.77, with a volume of 343700 shares changing hands. The stock had previously closed at $81.54.

A number of research firms have recently weighed in on ANAB. SunTrust Banks began coverage on shares of AnaptysBio in a research note on Wednesday, November 15th. They issued a “buy” rating and a $115.00 price target on the stock. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price target on the stock in a research note on Friday, November 10th. Jefferies Group began coverage on shares of AnaptysBio in a research note on Thursday, November 9th. They issued a “buy” rating and a $101.00 price target on the stock. Wedbush restated a “positive” rating and issued a $82.00 price target (up from $75.00) on shares of AnaptysBio in a research note on Tuesday, November 7th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $76.00 price target (up from $35.00) on shares of AnaptysBio in a research note on Friday, October 13th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $84.78.

The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. equities research analysts anticipate that AnaptysBio Inc will post -1.72 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of ANAB. Citadel Advisors LLC bought a new position in AnaptysBio in the 3rd quarter valued at approximately $20,406,000. Artal Group S.A. raised its holdings in AnaptysBio by 459.4% in the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after buying an additional 205,310 shares during the last quarter. VHCP Management II LLC bought a new position in AnaptysBio in the 3rd quarter valued at approximately $5,856,000. JPMorgan Chase & Co. raised its holdings in AnaptysBio by 210.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock valued at $6,363,000 after buying an additional 124,219 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new position in AnaptysBio in the 3rd quarter valued at approximately $2,796,000. Institutional investors and hedge funds own 75.45% of the company’s stock.

TRADEMARK VIOLATION WARNING: “AnaptysBio (ANAB) Reaches New 52-Week High at $84.75” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/02/anaptysbio-anab-reaches-new-52-week-high-at-84-75.html.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Stock Ratings for AnaptysBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc and related stocks with our FREE daily email newsletter.